Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
Biogen inked a binding deal to co-develop and co-commercialize Denali Therapeutics’ small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
Researchers at the University of Helsinki identified a molecule called BT13 that potentially can increase levels of dopamine.
Biogen Inc. agreed to buy an early-stage experimental treatment from Pfizer Inc. to test in patients with Alzheimer’s and Parkinson’s disease.
Researchers with Rockefeller University discovered something completely unexpected – the affected neurons in Parkinson’s disease may not be dead.
French researchers are developing what they say is the most powerful Magnetic Resonance Imaging (MRI) scanner in the world, which will use a supermagnet the weight of a blue whale and should allow earlier diagnosis of diseases such as Parkinson’s.
Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.
San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.
Merz North America announced today that the U.S. Food and Drug Administration accepted for filing a supplemental Biologics License Application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea (excessive drooling) due to Parkinson’s Disease or other neurologic disorders in adult patients.
